Skip to main content

Advertisement

SpringerLink
Log in

Role of Cytoreductive Nephrectomy in the Era of Targeted Therapy for Renal Cell Carcinoma

  • Kidney Diseases (G Ciancio, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

With the advent of targeted therapy for the treatment of metastatic renal cancer, the routine use of cytoreductive nephrectomy has been questioned. However, available data suggest that cytoreductive nephrectomy remains an integral part of treatment in properly selected patients. This review details the rationale for the continued use of cytoreductive nephrectomy in acceptable surgical candidates in the era of targeted therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Jeldres C, Baillargeon-Gagne S, Liberman D, et al. A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States. Urology. 2009;74:837–41.

    Article  PubMed  Google Scholar 

  2. Zini L, Capitanio U, Perrotte P, et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology. 2009;73:342–6.

    Article  PubMed  Google Scholar 

  3. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9.

    Article  PubMed  CAS  Google Scholar 

  4. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–70.

    Article  PubMed  CAS  Google Scholar 

  5. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071–6.

    Article  PubMed  Google Scholar 

  6. Lara Jr PN, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol. 2009;181:512–6.

    Article  PubMed  Google Scholar 

  7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.

    Article  PubMed  CAS  Google Scholar 

  8. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137–43.

    Article  PubMed  CAS  Google Scholar 

  9. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144–50.

    Article  PubMed  CAS  Google Scholar 

  10. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.

    Article  PubMed  CAS  Google Scholar 

  11. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8.

    Article  PubMed  CAS  Google Scholar 

  12. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.

    Article  PubMed  CAS  Google Scholar 

  13. Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010;116:3378–88.

    Article  PubMed  Google Scholar 

  14. •• Richey SL, Culp SH, Jonasch E, et al. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. 2011;22:1048–53. This article provides data on patients treated with targeted therapy alone and prognostic factors in this patient population.

    Google Scholar 

  15. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008;113:1552–8.

    Article  PubMed  CAS  Google Scholar 

  16. Karakiewicz PI, Sun M, Bellmunt J, Sneller V, Escudier B. Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria. Eur Urol. 2011;60:48–56.

    Article  PubMed  Google Scholar 

  17. •• Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794–9. The data provided in this article can be extremely useful for risk stratification of patients receiving targeted therapy for metastatic renal cancer.

    Article  PubMed  CAS  Google Scholar 

  18. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110:543–50.

    Article  PubMed  CAS  Google Scholar 

  19. Sun M, Shariat SF, Cheng C, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011; In press.

  20. You D, Jeong IG, Ahn JH, et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol. 2011;185:54–9.

    Article  PubMed  Google Scholar 

  21. •• Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185:60–6. This article provides initial data on the potential benefit of cytoreductive nephrectomy in patients receiving targeted therapy.

    Article  PubMed  Google Scholar 

  22. Russo P. Multi-modal treatment for metastatic renal cancer: the role of surgery. World J Urol. 2010;28:295–301.

    Article  PubMed  Google Scholar 

  23. Karam JA, Wood CG. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. Hematol Oncol Clin North Am. 2011;25:753–64.

    Article  PubMed  Google Scholar 

  24. •• Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011;117:2873–82. This article provides detailed data and discussion on the benefit of complete metastasectomy in metastatic renal cancer.

    Article  PubMed  Google Scholar 

  25. Di Lorenzo G, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011;59:526–40.

    Article  PubMed  Google Scholar 

  26. Barbastefano J, Garcia JA, Elson P, et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. 2010;106:1266–9.

    Article  PubMed  CAS  Google Scholar 

  27. Karam JA, Rini BI, Varella L, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011;185:439–44.

    Article  PubMed  Google Scholar 

  28. Bex A, Jonasch E, Kirkali Z, et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol. 2010;58:819–28.

    Article  PubMed  Google Scholar 

  29. Kutikov A, Uzzo RG, Caraway A, et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int. 2009;106:218–23.

    Article  PubMed  Google Scholar 

  30. •• Chapin BF, Delacroix SE, Jr., Culp SH, et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011;In press. This article is an extremely insightful description of postoperative complications in patients receiving presurgical therapy and provides initial outcome data.

  31. Powles T, Kayani I, Blank C, et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol. 2011;22:1041–7.

    Article  PubMed  CAS  Google Scholar 

  32. Rathmell WK, Pruthi R, Wallen E. Neoadjuvant treatment of renal cell carcinoma. Urol Oncol. 2010;28:69–73.

    Article  PubMed  CAS  Google Scholar 

  33. Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2009;181:518–23.

    Article  PubMed  CAS  Google Scholar 

  34. Abel EJ, Culp SH, Tannir NM, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011;59:10–5.

    Article  PubMed  Google Scholar 

  35. Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer. 2009;115:2355–60.

    Article  PubMed  Google Scholar 

  36. Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011; In press.

  37. Karnes RJ, Blute ML. Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus. Nat Clin Pract Urol. 2008;5:329–39.

    Article  PubMed  Google Scholar 

  38. Cost NG, Delacroix Jr SE, Sleeper JP, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011;59:912–8.

    Article  PubMed  CAS  Google Scholar 

  39. Patard JJ, Pignot G, Escudier B, et al. ICUD-EAU International consultation on kidney cancer 2010: treatment of metastatic disease. Eur Urol. 2011; In press.

  40. Abdollah F, Sun M, Thuret R, et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann Surg Oncol. 2011; In press.

  41. Polcari AJ, Gorbonos A, Milner JE, Flanigan RC. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Int J Urol. 2009;16:227–33.

    Article  PubMed  Google Scholar 

  42. Spiess PE, Fishman MN. Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma. Cancer Control. 2010;17:269–78.

    PubMed  Google Scholar 

  43. Chiong E, Wood CG, Margulis V. Role of cytoreductive nephrectomy in renal cell carcinoma. Future Oncol. 2009;5:859–69.

    Article  PubMed  Google Scholar 

  44. Abel EJ, Culp SH, Matin SF, et al. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol. 2010;184:1877–81.

    Article  PubMed  Google Scholar 

Download references

Disclosures

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Surgery, University of Kentucky, 800 Rose Street, MS235, Lexington, KY, 40513, USA

    Paul L. Crispen

  2. University of Massachusetts Medical School, 55 Lake Avenue North, Suite S4-868, Worcester, MA, 01655, USA

    Michael L. Blute

Authors
  1. Paul L. Crispen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael L. Blute
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael L. Blute.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crispen, P.L., Blute, M.L. Role of Cytoreductive Nephrectomy in the Era of Targeted Therapy for Renal Cell Carcinoma. Curr Urol Rep 13, 38–46 (2012). https://doi.org/10.1007/s11934-011-0225-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-011-0225-x

Keywords

Search

Navigation